Efficacy of Isoniazid Prophylaxis in Pediatric Patients at High Risk for LTBI Undergoing Hematopoietic Stem Cell Transplantation - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Efficacy of Isoniazid Prophylaxis in Pediatric Patients at High Risk for LTBI Undergoing Hematopoietic Stem Cell Transplantation

  • By

  • Uet Yu

  • Jiaming Yu

  • Xindan Lian

  • Yu Liu

  • Xiaodong Wang

  • Qian Zhang

  • Chunjing Wang

  • Chunlan Yang

  • Yue Li

  • Xiaohui Zhou

  • Xiaoling Zhang

  • Sixi Liu

  • February 2, 2026

Share

  • 1

    Pediatric HSCT recipients face a significantly higher TB incidence, necessitating effective prophylaxis due to immune suppression.

  • 2

    This study evaluated the efficacy of isoniazid prophylaxis in reducing post-HSCT TB reactivation in high-risk pediatric patients.

  • 3

    A total of 689 patients were analyzed, with 69 classified as LTBI high-risk based on positive IGRA results or radiological evidence.

  • 4

    Isoniazid was administered to high-risk patients starting 5-7 days post-HSCT for 6 months, with regular follow-up for adverse effects.

  • 5

    The study highlights the importance of TB risk stratification and targeted prophylaxis to prevent TB reactivation in vulnerable populations.

Original Source(s)

Related Content